James Bates

1.9K posts

James Bates banner
James Bates

James Bates

@JamesBatesMD

Asst Prof RadOnc @WinshipAtEmory #hncsm #lymsm @UF RadOnc | @UofR MD | @sunygeneseo BS Minimizing long-term effects of cancer. Tweets=mine

Atlanta, GA เข้าร่วม Haziran 2019
625 กำลังติดตาม1.7K ผู้ติดตาม
James Bates รีทวีตแล้ว
Steven J. Frank, MD
Steven J. Frank, MD@SJFrankMD·
A sincere appreciation and acknowledgment to the 440 patients, investigators, and institutions who participated on this Phase III randomized trial highlighting the ability of proton therapy (IMPT) to de-intensify treatment and improve survival @MDAndersonNews
UT MD Anderson@UTMDAnderson

Results from a study led by @SJFrankMD found a survival benefit for patients with oropharyngeal cancers treated with proton therapy than the patients receiving traditional radiation therapy. More on the findings, published today in @TheLancet: spr.ly/6014CDJfp #EndCancer

English
2
14
57
10.4K
James Bates
James Bates@JamesBatesMD·
This is a fantastic technique that brings real relief to patients - it is critical knowledge for all radiation oncologists who take inpatient call as we certainly all get called about this patient population!
Dr. Nina Niu Sanford@NiuSanford

Celiac plexus RT can alleviate intractable, narcotic-refractory pain, but target volumes may not be intuitive. We use guidelines from @LawrenceYaacov paper (PMID 39029483) to show the contouring approach, step by step. Plus other treatment planning pearls. Great job, Peter Lee!

English
0
3
7
2K
James Bates
James Bates@JamesBatesMD·
@ViewFromTheQ any updates on evening grounds access? worth a try this week?
English
0
0
1
951
The Q
The Q@ViewFromTheQ·
Qupdate Day 2 no point now, try after 4pm for late access.
English
22
5
35
32.4K
James Bates รีทวีตแล้ว
James Bates รีทวีตแล้ว
Dr Danish
Dr Danish@operationdanish·
This is the REAL problem with US Healthcare. Time to break them up.
Dr Danish tweet media
English
24
123
455
47.1K
James Bates รีทวีตแล้ว
OncoAlert
OncoAlert@OncoAlert·
Melanoma Among Adult Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study out on JCO buff.ly/4jeicCV This study investigated the incidence, risk factors, and outcomes of melanoma as a subsequent malignant neoplasm among childhood cancer survivors in the Childhood Cancer Survivor Study cohort. Among 25,716 participants, 177 melanomas developed in 160 survivors, with a 40-year cumulative incidence of 1.1%. Childhood cancer survivors had more than double the risk of developing invasive melanoma compared to the general population (SIR 2.0). Key risk factors included high-dose radiation (≥40 Gy), cyclophosphamide (≥20,000 mg/m²), and bleomycin exposure, all significantly associated with increased melanoma risk. Survivors who developed invasive melanoma faced over twice the risk of death (HR 2.4). These findings highlight the need for ongoing surveillance and risk management for melanoma in this population. @SethRotz @DrRebeccaHowel1 @JamesBatesMD
OncoAlert tweet media
English
0
4
11
1.4K
James Bates
James Bates@JamesBatesMD·
Very sad that I could not join in Athens - looks to be an incredible meeting and hope to be in-person at the next iteration!
Head and Neck Cancer International Group@H_N_C_I_G

The HNCIG currently holds its annual meeting in #Athens. With about 60 members attending in person and over 200 participants following the meeting online, it is a great achievement for the HNCIG. We have a lot of fruitful discussions here. Thanks for the great organisation!

English
0
0
4
420
James Bates
James Bates@JamesBatesMD·
Excited to speak about de-escalation in HPV+ oropharyngeal cancer and on late cardiac toxicity all in one meeting @somera_mx - very honored by the invite and the conference venue is truly breathtaking (Huatulco, Oaxaca)
James Bates tweet media
English
0
0
5
414
James Bates
James Bates@JamesBatesMD·
An amazing step forward in a relatively challenging to treat disease space that hasn't seen much progress in a long time. Look forward to seeing more results from this!
Michael Topf MD, MSCI@TopfHNS

merck.com/news/mercks-ke… A potential paradigm shifting result for oral cavity cancer - look forward to seeing the results! @HNSurgeon @DrUppaluri @JamesBatesMD @CJTsaiMDPhD @DavidSherMD @DrNeilGross @JamesBatesMD @BasuLab1 @EbenRosenthal @HeadNeckMD @JosephMCurryMD

English
0
0
7
918
James Bates
James Bates@JamesBatesMD·
98% PFS at 2 years in 70 Gy arm - will take really excellent selection tools to de-escalate with those results
C. Jillian Tsai, MD, PhD@CJTsaiMDPhD

‼️@sueyom presenting @NRGonc HN005 interim analysis @ASTRO_org #ASTRO24. Safe to say concurrent IO-RT (as of current field/delivery) is not beneficial across disease sites. But given all negative HN trials even for other drug studies thus far, where do we go from here? @imrtlee @xrtGenomics @seanmmcbride @IJROBP @yaoyu_md @DrJohndeAlmeida @xrtGenomics @JJCaudell @MFGensheimer @Qle_stanford @drlorenmell @JamesBatesMD @HenryParkMD @henson_md

English
2
1
10
1.3K
James Bates รีทวีตแล้ว
Pierre Blanchard, MD
Pierre Blanchard, MD@PBlanchardMD·
Congrats to my friend @YG_TAO & GORTEC for this huge trial of IO in LA HNSCC Avelumab-cetuximab inferior to cisplatin CRT in fit patients but superior to cetuximab-RT for PFS in cisplatin ineligible population. #ESMO2024
Pierre Blanchard, MD tweet mediaPierre Blanchard, MD tweet mediaPierre Blanchard, MD tweet mediaPierre Blanchard, MD tweet media
English
1
28
58
6.5K